Eton Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Eton Pharmaceuticals, Inc. (ETON) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $6.24 per share as of 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-05-14
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $6.24.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $5.35.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $5.34.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $5.32.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-03-31 | $6.24 10-Q · filed 2026-05-14 |
| 2025-12-31 | $5.35 10-K · filed 2026-03-19 |
| 2025-09-30 | $5.34 10-Q · filed 2025-11-06 |
| 2025-06-30 | $5.32 10-Q · filed 2025-08-07 |
| 2025-03-31 | $5.29 10-Q · filed 2025-05-13 |
| 2024-12-31 | $4.65 10-K · filed 2025-03-18 |
| 2024-09-30 | $4.53 10-Q · filed 2025-11-06 |
| 2024-06-30 | $4.54 10-Q · filed 2025-08-07 |
| 2024-03-31 | $4.54 10-Q · filed 2024-05-09 |
| 2023-12-31 | $4.57 10-K · filed 2024-03-14 |
| 2023-09-30 | $4.58 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.61 10-Q · filed 2023-08-10 |
| 2023-03-31 | $4.68 10-Q · filed 2023-05-11 |
| 2019-03-31 | $3.67 10-Q · filed 2019-05-07 |
| 2018-12-31 | $1.79 10-K · filed 2019-03-25 |
| 2018-09-30 | $1.45 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |